(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 October 2025 (23.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/222169 A1

(51) International Patent Classification:
A61K 31/138 (2006.01) *A61P 3/10* (2006.01)
A61K 38/26 (2006.01) *A61P 21/06* (2006.01)
A61K 45/06 (2006.01) *A61K 31/404* (2006.01)
A61P 3/04 (2006.01)

(21) International Application Number:
PCT/US2025/025447

(22) International Filing Date:
18 April 2025 (18.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/636,664	19 April 2024 (19.04.2024)	US
63/668,732	08 July 2024 (08.07.2024)	US
2410016.6	10 July 2024 (10.07.2024)	GB
2415544.2	22 October 2024 (22.10.2024)	GB
2500384.9	13 January 2025 (13.01.2025)	GB

(71) Applicants: **FARADAY PHARMACEUTICALS, INC.** [US/US]; 1616 Eastlake Avenue E, Suite 560, Seattle, Washington 98102 (US). **ACTIMED THERAPEUTICS LTD** [GB/GB]; The Old Bakehouse, Course Road, Ascot Berkshire SL5 7HL (GB).

(72) Inventors: **INSKO, Michael A.**; c/o Faraday Pharmaceuticals, Inc., 1616 Eastlake Avenue E, Suite 560, Seattle, 98102 (US). **ROCK, Patrick C.**; c/o Faraday Pharmaceuticals, Inc., 1616 Eastlake Avenue E, Suite 560, Seattle, 98102 (US). **HILL, Stephen A.**; c/o Faraday Pharmaceuticals, Inc., 1616 Eastlake Avenue E, Suite 560, Seattle, Washington 98102 (US). **SIEGEL, Lori A.**; c/o Faraday Pharmaceuticals, Inc., 1616 Eastlake Avenue E, Suite 560, Seattle, Washington 98102 (US). **BOCKUS, Lee B.**; c/o Faraday Pharmaceuticals, Inc., 1616 Eastlake Avenue E,

(54) Title: S-OXPRENOLOL FOR PRESERVING MUSCLE MASS, BONE DENSITY, AND CARDIAC FUNCTION IN WEIGHT LOSS TREATMENTS




FIG. 18A

(57) Abstract: The present invention relates to a beta-blocker for use in a method for preventing, inhibiting, or reducing loss of muscle mass and/or function and/or bone density in a subject resulting from a weight loss treatment, which method comprises providing to the subject an effective amount of the beta-blocker. The invention also relates to a beta-blocker for use in a method for protecting cardiac muscle and/or cardiac function in a subject during a weight loss treatment, or for protecting against hypotension and/or increased heartrate in a subject during a weight loss treatment, which method comprises providing to the subject an effective amount of the beta-blocker. The invention further relates to a beta-blocker for use in a method for increasing or restoring muscle mass and/or function and/or bone density in a subject following a weight loss treatment, which method comprises providing to the subject an effective amount of the beta-blocker.

WO 2025/222169 A1

[Continued on next page]

Suite 560, Seattle, 98102 (US). **ANKER, Stefan**; c/o Actimed Therapeutics Ltd, The Old Bakehouse, Course Road, Ascot Berkshire SL5 7HL (GB). **COATS, Andrew**; c/o Actimed Therapeutics Ltd, The Old Bakehouse, Course Road, Ascot Berkshire SL5 7HL (GB). **BHATTACHERJEE, Robin**; c/o Actimed Therapeutics Ltd, The Old Bakehouse, Course Road, Ascot Berkshire SL5 7HL (GB). **MORTEN, Elaine**; c/o Actimed Therapeutics Ltd, The Old Bakehouse, Course Road, Ascot Berkshire SL5 7HL (GB).

(74) **Agent: LAHERTY, Carol D.** et al.; Cooley LLP, ATTN: IP Docketing Department, 1299 Pennsylvania Avenue NW, Suite 700, Washington, 20004-2400 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*